Merck Drugs Tied To Lingering Sex Disorders, FDA Warns

Law360, New York (April 12, 2012, 8:28 PM EDT) -- Merck & Co. Inc. drugs for baldness and enlarged prostate are linked to problems with libido, orgasms and other sexual functions even after individuals stop using them, the U.S. Food and Drug Administration said Wednesday, after previously finding the drugs increase risks of prostate cancer.

The FDA is expanding the labels for Merck male-pattern baldness drug Propecia to warn consumers of links to libido disorders, ejaculation disorders and orgasm disorders after it is discontinued, and the agency is adding warnings to the prostate drug Proscar of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.